'
Zydus
Lifesciences hosted a conference call on Aug 12, 2025. In the conference call,
the company was represented by, Dr. Sharvil Patel, Managing Director.
Key takeaways of the call
In
Q1 FY25, the India Formulations business grew 8% YoY, Consumer Wellness was up
2.2% YoY, US Formulations rose 2.9% YoY, and International Formulations
increased 36.8% YoY. Revenue from the API segment increased 11.3% YoY, and the
Alliances & Others segment was down 27.9% YoY.
India
Branded formulations business grew faster than the market with 9% YoY growth in
Q1 FY26 driven by a strong uptick in pillar brands and innovation products.
Chronic segment also continued strong growth.
In
Q1 FY26, Cardio-Diabeto contributed 16% to India Formulations segment revenue,
Respi 13%, Gynae 6%, Onco 9%, Nephro 4%, Hepato 2%, GI 9%, Derma 6%, Pain 8%,
Anti-infectives 13%, and others 14%.
Pleaselogin & subscribe to view the full report.
More Reports
-
(05-Feb-2025)
Castrol India
Expects EBITDA margin of 22%-25% for CY25
-
(10-Feb-2023)
Deepak Nitrite
Plans capex of about Rs 1500 crore for FY23 and FY24
-
(09-Feb-2023)
Mayur Uniquoters
Targets revenue of Rs 1000 crore in FY24
-
(31-Jan-2023)
Tega industries
Capex plan is US$ 30-32 million for next three years
|
|